BioTherapeutics Inc.

2.1K posts

BioTherapeutics Inc. banner
BioTherapeutics Inc.

BioTherapeutics Inc.

@BioTherap

Official @BioTherap site for Health News and Precision Medicine Innovation #PrecisionMedicine #Informatics #AI #MachineLearning #PredictiveAnalytics #Modeling

Blacksburg, VA Katılım Temmuz 2015
3K Takip Edilen3.3K Takipçiler
BioTherapeutics Inc. retweetledi
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Listen to our Founder & CEO, Dr. Josep Bassaganya-Riera, on the @BioWorld Insider podcast, where he discusses how NImmune is leveraging the TITAN-X AI platform to advance precision medicine in inflammatory and autoimmune diseases. Listen here: bioworld.com/media/podcasts…
NImmune Biopharma tweet media
English
0
2
3
186
BioTherapeutics Inc. retweetledi
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Today on #WorldIBDDay, we stand with the global IBD community in the fight against Crohn’s disease and ulcerative colitis. At NImmune, our team is advancing omilancor, a first-in-class oral therapeutic targeting LANCL2, now in Phase 3.
NImmune Biopharma tweet media
English
0
2
3
162
BioTherapeutics Inc. retweetledi
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
New #DDW2025 data: once-daily oral omilancor outperformed anti-TL1A in IBD on efficacy & safety. Results show reversal of Treg depletion & mitochondrial dysfunction in UC. Best-in-class profile supports NDA path by 2027. Read more: businesswire.com/news/home/2025…
NImmune Biopharma tweet media
English
0
1
4
48
BioTherapeutics Inc. retweetledi
The NIMML Institute
The NIMML Institute@NIMMLab·
New data presented at #DDW2025 shows LANCL2 activation via omilancor outperforms anti-TL1A in IBD. Backed by our TITAN-X A.I. platform, results show superior efficacy, unmatched safety, and reversal of Treg/mitochondrial dysfunction in UC. Read more: businesswire.com/news/home/2025…
The NIMML Institute tweet media
English
0
1
4
111
BioTherapeutics Inc. retweetledi
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Thrilled to share that our Founder & CEO, Dr. Josep Bassaganya-Riera, was featured on @LaunchBio’s NextGen VC podcast to discuss his journey building Landos Biopharma from new scientific findings to a $600M market cap company. Listen here: launchbio.org/nextgen-vc-pod…
NImmune Biopharma tweet media
English
0
2
3
62
BioTherapeutics Inc. retweetledi
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Thrilled to see @NIMMLab’s new #TITANX applications in @AnnualReviews. This #AI platform is driving our drug pipeline, from omilancor to NIM-1324, accelerating #PrecisionMedicine for #immunology. Keep innovating!
The NIMML Institute@NIMMLab

Excited to share new case studies in @AnnualReviews showing how our TITAN-X #AI platform fuels next-gen #immunology & #inflammation therapies. By unlocking novel targets like LANCL2, we’re advancing #PrecisionMedicine. Read the peer-reviewed article here: annualreviews.org/content/journa…

English
0
1
2
46
BioTherapeutics Inc. retweetledi
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Check out our Founder & CEO, Dr. Josep Bassaganya-Riera, on the Life Science & Biotech CEO Stories podcast as he shares his success story and how he's leading the charge in applying A.I. to biotech innovation. Listen here: biotechinsights.net/post/he-s-sett…
NImmune Biopharma tweet media
English
0
2
2
51
BioTherapeutics Inc. retweetledi
The NIMML Institute
The NIMML Institute@NIMMLab·
We are pleased to announce that new data from two IBD studies will be presented at @DDWMeeting. The studies focus on the best-in-class efficacy and safety, novel mechanism and combination therapies of omilancor & TL1A. Read more: #DDW2025" target="_blank" rel="nofollow noopener">nimml.org/news/detail/ni…
The NIMML Institute tweet media
English
0
1
2
77
BioTherapeutics Inc. retweetledi
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
We are pleased to announce that new data from two IBD studies will be presented at @DDWMeeting. The studies focus on the best-in-class efficacy and safety profile, novel mechanism and combination therapies of omilancor & TL1A. Read more: #DDW2025" target="_blank" rel="nofollow noopener">businesswire.com/news/home/2025…
NImmune Biopharma tweet media
English
0
1
3
57
BioTherapeutics Inc. retweetledi
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Excited to share publication of positive Phase 1 results for NIM-1324 in treating Systemic Lupus Erythematosus! This milestone highlights our commitment to precision medicine and addressing unmet needs in immune-mediated diseases. Kudos to @NIMMLab for the collaboration!
The NIMML Institute@NIMMLab

Our paper on Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus, was accepted to the #CTSJournal! Findings validated NIM-1324 as a well-tolerated treatment for SLE. Read it in @ASCPTjournals: #ASCPTJournalFamily" target="_blank" rel="nofollow noopener">nimml.org/news/detail/th…

English
0
1
1
46
BioTherapeutics Inc. retweetledi
The NIMML Institute
The NIMML Institute@NIMMLab·
Our paper on Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus, was accepted to the #CTSJournal! Findings validated NIM-1324 as a well-tolerated treatment for SLE. Read it in @ASCPTjournals: #ASCPTJournalFamily" target="_blank" rel="nofollow noopener">nimml.org/news/detail/th…
The NIMML Institute tweet media
English
0
2
3
174
BioTherapeutics Inc. retweetledi
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
We are pleased to share that NImmune will be attending #JPM2025 in San Francisco from January 13–16! We look forward to engaging in impactful conversations, connecting with industry leaders, and building our network to start 2025 on a strong note.
NImmune Biopharma tweet media
English
0
2
2
83
BioTherapeutics Inc. retweetledi
The NIMML Institute
The NIMML Institute@NIMMLab·
A recent study from researchers at @CUNYNeuro finds promising new therapeutic potential in the treatment of Alzheimer’s disease for LANCL2 drugs, further validating our TITAN-X precision medicine platform in new indication. Read the full paper here: biorxiv.org/content/10.110…
The NIMML Institute tweet media
English
0
2
2
131
BioTherapeutics Inc.
BioTherapeutics Inc.@BioTherap·
Thrilled our sister company @NImmuneBio is featured in Valley Business FRONT! As part of Virginia’s BioHealth Innovation ecosystem, we’re proud of their groundbreaking immunology R&D. Together with Dr. Bassaganya-Riera, we’re pushing biotech boundaries. Congrats, NImmune team!
NImmune Biopharma@NImmuneBio

Excited to be featured in Valley Business FRONT! Our CEO Dr. Bassaganya-Riera discusses Nimmune’s role in Virginia’s BioHealth innovation ecosystem. We’re pushing boundaries in immunology with AI-driven drug development and transformative clinical trials. issuu.com/berryfield5/do…

English
0
0
0
41
BioTherapeutics Inc. retweetledi
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
On Oct. 21, we acquired development and commercialization rights for omilancor in Greater China. We now wholly own global rights to omilancor, the best-in-class therapy for ulcerative colitis and other I&I indications. Read the full announcement: nimmunebio.com/nimmune-biopha…
NImmune Biopharma tweet media
English
0
2
0
70
BioTherapeutics Inc. retweetledi
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Research published in @J_Immunol validates NIM-1324 as the first LANCL2 agonist effective in systemic inflammation across 3 in vivo lupus models. Read more about how @NIMMLab is making groundbreaking mechanistic discoveries: nimmunebio.com/the-nimml-inst…
NImmune Biopharma tweet media
English
0
2
3
79

Keşfet

@BioWorld @LaunchBio @NIMMLab @AnnualReviews @FrontiersIn @DDWMeeting @ASCPTjournals @CUNYNeuro